Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
SUNY Downstate Health Sciences University · Addenbrooke's Hospital · +2 more institutions
Abstract
Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, controlled trial. Here, we report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a multinational, two-phase (induction and maintenance) study. We randomly assigned 370 patients with classes III through V lupus nephritis to open-label MMF (target dosage 3 g/d) or IVC (0.5 to 1.0 g/m(2) in monthly pulses) in a 24-wk induction study. Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d. The primary end point was a…
Citation impact
- FWCI
- 51.38
- Percentile
- 100%
- References
- 36
Authors
11- GBGerald B. AppelCorresponding
SUNY Downstate Health Sciences University, Addenbrooke's Hospital, University College London, Columbia University
- GCGabriel Contreras
SUNY Downstate Health Sciences University, Addenbrooke's Hospital, University College London
- MAMary Anne Dooley
SUNY Downstate Health Sciences University, Addenbrooke's Hospital, University College London
- EMEllen M. Ginzler
SUNY Downstate Health Sciences University, Addenbrooke's Hospital, University College London
- DIDavid Isenberg
SUNY Downstate Health Sciences University, Addenbrooke's Hospital, University College London
Topics & keywords
- Lupus nephritis
- Medicine
- Cyclophosphamide
- Adverse effect
- Clinical endpoint
- Prednisone
- Creatinine
- Gastroenterology
- Good health and well-being